Sarepta Therapeutics Inc (SRPT)
Operating return on assets (Operating ROA)
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | -94,831 | -267,824 | -399,282 | -509,795 | -587,408 | -536,201 | -535,181 | -438,284 | -394,726 | -459,710 | -524,613 | -627,223 | -598,002 | -564,163 | -623,666 | -610,188 | -747,202 | -705,563 | -614,707 | -561,216 |
| Total assets | US$ in thousands | 3,224,380 | 3,264,580 | 3,109,710 | 3,125,890 | 3,059,790 | 3,128,370 | 3,156,150 | 2,996,850 | 3,056,150 | 3,147,970 | 2,662,220 | 2,759,070 | 2,765,230 | 2,984,720 | 2,780,660 | 2,883,040 | 2,947,390 | 1,822,820 | 1,702,470 | 1,747,750 |
| Operating ROA | -2.94% | -8.20% | -12.84% | -16.31% | -19.20% | -17.14% | -16.96% | -14.62% | -12.92% | -14.60% | -19.71% | -22.73% | -21.63% | -18.90% | -22.43% | -21.16% | -25.35% | -38.71% | -36.11% | -32.11% |
March 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $-94,831K ÷ $3,224,380K
= -2.94%
Sarepta Therapeutics Inc's operating return on assets (ROA) has experienced fluctuating performance over the past two years. The operating ROA measures the company's ability to generate profits from its assets solely from its core operations.
From the provided data, it is evident that Sarepta Therapeutics Inc's operating ROA has been negative in most quarters, indicating that the company's core operations have not been generating sufficient returns relative to its assets. The declining trend in operating ROA throughout the quarters suggests a possible inefficiency in the company's operational management, profitability, or asset utilization.
The magnitude of the negative operating ROA percentages indicates the extent to which the company's operations are not effectively generating returns from its assets. The downward trajectory of the operating ROA from -2.94% in March 2024 to -32.11% in June 2019 highlights a concerning trend of decreasing profitability relative to assets over this period.
In conclusion, the consistent negative operating ROA figures suggest that Sarepta Therapeutics Inc may need to focus on improving the efficiency of its core operations to enhance profitability and better utilize its assets to generate sustainable returns in the future.
Peer comparison
Mar 31, 2024